Home > Insider Trading > Filing (0000899243-19-029699)

Filing Details

Accession Number:: 0000899243-19-029699
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-12-19 20:54:26
Reporting Period:: 2019-12-17

Accepted Time:: 2019-12-19 20:54:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1259856	Douglas Fambrough	C/O Dicerna Pharmaceuticals, Inc. 33 Hayden Avenue Lexington MA 02421	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-12-17	56,716	$26.13	14,605	No	4	S	Direct
Common Stock	Disposition	2019-12-17	2,305	$26.94	12,300	No	4	S	Direct
Common Stock	Acquisiton	2019-12-18	80,000	$3.42	92,300	No	4	M	Direct
Common Stock	Disposition	2019-12-18	78,569	$25.85	13,731	No	4	S	Direct
Common Stock	Disposition	2019-12-18	1,431	$27.07	12,300	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2019-12-18	80,000	$0.00	80,000	$3.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
201,250		2023-09-24	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.79, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of to Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.82 to $27.08, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.60 to $26.5950, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.87 to $27.1950, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
Vested 1/48 monthly on last day of each month with a vesting start date of 07/30/2013.